Mindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
Mindset Pharma Inc. (OTCQB: MSSTF), a leader in developing next-generation psychedelic medicines, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. CEO James Lanthier will join the Future of Mental Healthcare panel at 2:30 p.m. ET, with his corporate presentation available on-demand from 7:00 a.m. ET. Mindset focuses on drug discovery to address neurological and psychiatric disorders, creating optimized psychedelic compounds and innovating psilocybin synthesis. More details can be found on their website.
- None.
- None.
TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.
James Lanthier, CEO of Mindset, will participate in the Future of Mental Healthcare panel at 2:30 p.m. ET. To attend, register here.
In addition, Mr. Lanthier’s corporate presentation will be available on-demand starting at 7:00 a.m. ET.
For more information about the conference, or to schedule a one-on-one meeting with Mindset's management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at lk@hcwco.com, or KCSA Strategic Communications at MindSet@kcsa.com.
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
For further information on Mindset, please visit our website at www.mindsetpharma.com.
For more information, please contact:
Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com
Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FAQ
What is Mindset Pharma participating in on December 6, 2021?
Who will represent Mindset Pharma at the conference?
What time is the Future of Mental Healthcare panel?
Where can I find Mindset Pharma's corporate presentation?
What is the focus of Mindset Pharma's development efforts?
